Because of the increase in sensitivity for relapse detection, in acute leukemia patients, we also perform chimerism analysis in unseparated BM (as well as in BM-isolated CD34+ cells in CD34+ neoplasms) every three months for the first year after HSCT and every six months for the second year. The gene discussed is CD34; the disease is acute leukemia.